Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors

On June 11, 2026 Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, reported that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1617, a potential first-in-class ADC directed at an undisclosed solid tumor target and incorporating HC74, Immunome’s proprietary TOP1 inhibitor payload.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The first patient dosed with IM-1617 is a significant milestone for Immunome’s ADC platform and a meaningful step toward our mission of delivering targeted therapies for patients with cancer," said Clay Siegall, Ph.D., President and Chief Executive Officer of Immunome. "We are encouraged by the pace of progress across our portfolio and look forward to advancing IM-1617 while continuing to expand the clinical potential of our proprietary HC74 payload through additional ADC programs."

The Phase 1 trial is an open-label, multicenter dose escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of IM-1617. The study is expected to include participants with advanced solid tumors, including colorectal cancer, non-small cell lung cancer, and breast cancer.

About IM-1617

IM-1617 is a clinical-stage solid tumor ADC. It targets an undisclosed receptor tyrosine kinase that promotes tumor cell survival and mediates immune cell exclusion, and it incorporates HC74, Immunome’s proprietary TOP1 inhibitor. Preclinical in vivo efficacy studies showed impressive tumor regression after a single, clinically relevant dose of IM-1617 in a variety of solid tumor models.

(Press release, Immunome, JUN 11, 2026, View Source [SID1234666588])